⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 15 in last 7 days 🍎 Food: 1 in last 7 days 🧸 Products: 52 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 2 hours ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 15 in last 7 days 🍎 Food: 1 in last 7 days 🧸 Products: 52 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 2 hours ago
🛡️ EUSW
🇬🇧
💊

Abraxane

paclitaxel
Breast Neoplasms;Pancreatic Neoplasms;Carcinoma, Non-Small-Cell Lung
✅ Authorised
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated. Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.

⚠️ Patient safety

No

📚 Past alerts (2)
⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.